International Journal of Hematology

, Volume 85, Issue 4, pp 344–349 | Cite as

Selective Blast Cell Reduction in Elderly Patients with Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome Treated with Methylprednisolone

  • Kei Suzuki
  • Kohshi Ohishi
  • Takao Sekine
  • Masahiro Masuya
  • Naoyuki Katayama
Case Report


The management of elderly patients with acute myeloid leukemia (AML) and a poor performance status is challenging. An 89-year-old man with AML secondary to myelodysplastic syndrome (MDS) and a poor performance status (4) underwent treatment with methylprednisolone (mPSL) (125 mg/body), which resulted in a remarkable reduction of blast cells in the peripheral blood. Neutrophil counts were maintained or increased. Although the suppression was of short duration, mPSL was useful for disease control because it selectively reduced blast counts while maintaining the patient’s performance status. In vivo and in vitro findings suggested that mPSL had direct inhibitory actions on the survival of blast cells. On the basis of this experience, we gave the same mPSL dose to other elderly patients with MDS/AML (n = 5) or AML-M4 (n = 1) who had a poor performance status (3 or higher) and appeared unable to tolerate standard cytotoxic chemotherapies. Selective and significant blast cell reduction was observed in 4 of the 5 patients with MDS/AML, whereas no effects were seen in the AML patient. Although our experience is limited, these findings may provide a clue to understanding the mechanisms regulating the survival of blast cells of MDS/AML and indicate that mPSL may provide a benefit to a subset of these patients.

Key words

Methylprednisolone Acute myeloid leukemia Myelodysplastic syndrome Apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deschler B, de Wittle T, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica.2006;91:1513–1522.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Latagliata R, Petti MC, Mandelli F. Acute myeloid leukemia in the elderly: ’per aspera ad astra’? Leuk Res. 1999;23:603–613.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363–371.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Boggs DR, Wintrobe MM, Cartwright GE. The acute leukemias: analysis of 322 cases and review of the literature. Medicine (Baltimore). 1962;41:163–225.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Kaspers GJL, Pieters R, Klumper E, De Waal FC, Veerman AJ. Glucocorticoid resistance in childhood leukemia. Leuk Lym-phoma. 1994;13:187–201.CrossRefGoogle Scholar
  7. 7.
    Hill JM, Marshall GJ, Falco DJ. Massive prednisone and pred-nisolone therapy in leukemia and lymphomas in the adult. J Am Geriatr Soc. 1956;4:627–641.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Ranney HM, Gellhorn A. The effect of massive prednisone and pred-nisolone therapy on acute leukemia and malignant lymphomas. Am J Med. 1957;22:405–413.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Shanbrom E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med. 1962;266:1354–1358.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Hiçsönmez G. The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelo-poiesis. Leuk Res. 2006;30:60–68.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Hiçsönmez G, Cetin M, Tuncer AM, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltra- tion: the effects of high-dose steroid treatment. Leuk Res. 2004;28:25–34.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Hiçsönmez G, Cetin M, Yenicesu I, et al. Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. Leuk Lymphoma. 2001;42:665–674.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Parker JE, Mufti GJ. The myelodysplastic syndromes: a matter of life or death. Acta Haematol. 2004;111:78–99.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Braun T, Carvalho G, Coquelle A, et al. NF-?B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107:1156–1165.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-: B and steroid receptor-signaling pathways. Endocr Rev. 1999; 20:435–459.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-?B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Morgan MA, Reuter CWM. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol. 2006;85:139–163.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Kei Suzuki
    • 1
  • Kohshi Ohishi
    • 2
  • Takao Sekine
    • 1
  • Masahiro Masuya
    • 3
  • Naoyuki Katayama
    • 2
  1. 1.Internal MedicineMatsusaka Chuo General HospitalMieJapan
  2. 2.Department of Hematology and OncologyMie University Graduate School of MedicineMieJapan
  3. 3.Blood Transfusion ServiceMie University HospitalMieJapan

Personalised recommendations